The Ministry of Health’s rollout of free lenacapavir, a revolutionary twice-yearly injectable for HIV prevention, marks one of the most significant public health shifts in Uganda’s recent history. By moving away from daily pills to a biannual injection, Uganda is not only changing how HIV is prevented, but also reshaping the long-term economic and logistical burden of managing the epidemic.
For decades, Pre-Exposure Prophylaxis (PrEP) relied on strict daily adherence to oral medication. While effective in theory, this approach struggled in practice. Many people faced challenges such as stigma, treatment fatigue, and the inconvenience of frequent clinic visits. These barriers were even more pronounced among young people, mobile workers, and rural communities with limited access to health facilities.
Lenacapavir, manufactured by the American biopharmaceutical company Gilead Sciences, changes this dynamic entirely. Administered as a subcutaneous injection once every six months, it significantly reduces the burden on patients and health systems alike. Instead of twelve clinic visits a year, individuals only need two. For populations such as long-distance truck drivers and rural farmers, this shift dramatically improves accessibility and consistency of prevention.
The National Drug Authority (NDA) has approved the drug for preventive use following a comprehensive review of clinical data. This approval was strongly informed by the PURPOSE 1 clinical trials, conducted across Uganda and South Africa, which demonstrated near-complete efficacy in preventing HIV among cisgender women. The safety profile is also considered strong, with most side effects limited to mild and temporary injection site reactions such as swelling or discomfort. Health authorities, however, have issued guidance against combining the injection with certain tuberculosis medications due to potential drug interactions.
Beyond its medical impact, the introduction of lenacapavir carries significant economic implications. Uganda continues to record tens of thousands of new HIV infections annually, each one representing a long-term financial commitment to antiretroviral treatment and ongoing care. Preventing infections at scale therefore reduces future public health expenditure and strengthens fiscal sustainability.
Although the initial supply has been supported through global health partnerships, including the Global Fund, long-term affordability depends on expanded generic production. Research suggests that the annual cost per person could eventually fall to between $25 and $46, making large-scale prevention financially realistic for developing health systems. In this sense, prevention becomes not just a health intervention, but a cost-saving economic strategy.
For businesses, the implications are equally important. HIV disproportionately affects the working-age population, contributing to absenteeism, reduced productivity, and higher corporate healthcare costs. A successful rollout of long-acting prevention could strengthen workforce stability and reduce these economic disruptions over time.
For ordinary Ugandans, the shift means simpler, more reliable protection without the burden of daily medication. It also reflects a broader transformation in public health strategy, where high-impact, low-maintenance solutions are increasingly prioritized.
Ultimately, Uganda’s adoption of twice-yearly HIV prevention is more than a medical advancement. It is a structural shift in how health, productivity, and long-term public spending intersect. If effectively scaled, it could become one of the most important public health and economic interventions of the decade.